Vectus Biosystems (ASX:VBS) Pre-Tax Income

: A$-3.45 Mil (TTM As of Dec. 2022)

View and export this data going back to 2016. Start your Free Trial

Pretax income is the income that a company earns before paying income taxes. Vectus Biosystems's pretax income for the six months ended in Dec. 2022 was A$-2.14 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2022 was A$-3.45 Mil. Vectus Biosystems's pretax margin was -23,766.67%.

During the past 8 years, Vectus Biosystems's highest Pretax Margin was -38322.22%. The lowest was -80316.67%. And the median was -80316.67%.

Vectus Biosystems Pre-Tax Income Historical Data

The historical data trend for Vectus Biosystems's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Pre-Tax Income

-2.50

-3.38

-4.80

-3.99

-3.45

Vectus Biosystems Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Pre-Tax Income											-2.64	-2.55	-1.45	-2.14	-1.31

Competitive Comparison

For the Biotechnology subindustry, Vectus Biosystems's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Vectus Biosystems Pre-Tax Income Distribution

For the Biotechnology industry and Healthcare sector, Vectus Biosystems's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Vectus Biosystems's Pre-Tax Income falls in comparison to its industry or sector. The grey bar indicates the Pre-Tax Income's extreme value range as defined by GuruFocus.

Vectus Biosystems Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Vectus Biosystems's Pretax Income for the fiscal year that ended in Jun. 2022 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-4.6	+	1.3	+	-0.693	+	0	+	-0.0010000000000008
	=	-3.99

Vectus Biosystems's Pretax Income for the quarter that ended in Dec. 2022 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-2.508	+	0.563	+	-0.2	+	0.007	+	-0.00099999999999945
	=	-2.14

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-3.45 Mil.

Vectus Biosystems (ASX:VBS) Pre-Tax Income Explanation

Vectus Biosystems's Pretax Margin for the quarter that ended in Dec. 2022 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-2.139	/	0.009
	=	-23,766.67%

During the past 8 years, Vectus Biosystems's highest Pretax Margin was -38322.22%. The lowest was -80316.67%. And the median was -80316.67%.

Vectus Biosystems Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Vectus Biosystems (ASX:VBS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018

Website

https://www.vectusbiosystems.com.au

Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines